Motus GI Hlds

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in 2008 and is headquartered in Fort Lauderdale, FL.

Implementation of the Pure-Vu System is designed to improve efficiencies and outcomes of GI endoscopy procedures Implementation of the Pure-Vu System is designed to improve efficiencies and outcomes of GI endoscopy procedures

Motus GI's Pure-Vu System® Adopted by Sinai Hospital of Baltimore

Blue Hat Interactive Entertainment Technology

BIOLASE

Castor Maritime Inc

Golden Minerals Company

Waitr Holdings Inc

It can be difficult to find cheap stocks worth buying. But these seven companies look promising and are all under $3.

7 Cheap Stocks to Buy Now Under $3

Motus GI Holdings, Inc (MOTS) CEO Tim Moran on Q1 2021 Results - Earnings Call Transcript

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of -10.00% and 27.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Motus GI Holdings, Inc. (MOTS) Reports Q1 Loss, Tops Revenue Estimates

Shares of Motus GI Hldgs (NASDAQ:MOTS) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 52.17% year over year to ($0.11), which missed the estimate of ($0.10).

Recap: Motus GI Hldgs Q1 Earnings

FORT LAUDERDALE, Fla., May 13, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the first quarter ended March 31, 2021, and provided a corporate update.

Motus GI Reports First Quarter 2021 Financial Results and Provides Corporate Update

- - - - The article states Pure-Vu System is estimated to provide lifetime saving of $833- $992 per patient when compared to standard of care for outpatient colorectal cancer (CRC) screening and surveillance colonoscopy - - - - The researchers indicated that approximately 25% of 15 million outpatient colonoscopies performed annually in the US, or 3.75 million are inadequately prepped - - - - The article indicates that quality of life may be improved with the Pure-Vu System due primarily to a potential lower incidence of Colorectal Cancers as a result of early detection.

Motus GI Announces Publication of a Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource Allocation

Motus GI Holdings (MOTS) stock is on the rise Friday following clearance from the FDA for one of the company's medical devices. The post MOTS Stock: The Big FDA News That Has Motus GI Holdings Soaring Today appeared first on InvestorPlace.

MOTS Stock: The Big FDA News That Has Motus GI Holdings Soaring Today

Clear Channel Outdoor Holdings

Nokia

Tech penny stocks are back in focus; check these 3 out The post Penny Stocks to Buy? Check These Tech Stocks Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Buy? Check These Tech Stocks Out

The stock price of Motus GI Holdings Inc (NASDAQ: MOTS) increased by over 45% pre-market. This is why it happened.

MOTS Stock: From $1.09 To Over $1.60 Pre-Market Explanation

FORT LAUDERDALE, Fla., April 30, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for a version of the Pure-Vu® System that is compatible with gastroscopes used during upper gastrointestinal (GI) endoscopy procedures to remove blood, blood clots and debris in order to provide a clear field-of-view for the endoscopist. This proprietary technology is the latest innovation for the Pure-Vu System platform that is specifically designed to integrate with therapeutic gastroscopes to enable safe and rapid cleansing during the procedure, while preserving established procedural workflow and techniques.

Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy

FORT LAUDERDALE, Fla., April 29, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its first quarter financial results on Thursday, May 13, 2021, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.

Motus GI to Release First Quarter Results and Provide a Business Update on May 13

Motus GI Holdings Inc (NASDAQ: MOTS) has submitted a 510(k) application to the FDA for a version of the Pure-Vu System. The new version of the system is compatible with gastroscopes used during upper gastrointestinal (GI) endoscopy procedures to remove blood, blood clots, and debris to provide a clear field-of-view for the endoscopist.

Motus Files Pure-Vu Version US Application For Use During Upper GI Endoscopy

The stock price of Motus GI Holdings (NASDAQ: MOTS) increased by over 2% pre-market. This is why it happened.

Motus GI Stock Price Increased Over 2% Pre-Market: Why It Happened

Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q4 2020 Results - Earnings Call Transcript

FORT LAUDERDALE, Fla., March 16, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the fourth quarter ended December 31, 2020, and provided a corporate update.

Motus GI Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update

FORT LAUDERDALE, Fla., March 15, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today the enrollment of the first patient in a pilot study of the Pure-Vu® System. The study is evaluating the clinical and economic outcomes using the Pure-Vu System in patients with emergent lower gastrointestinal bleeding that are evaluated and treated in the Intensive Care Unit (ICU) or the rapid inpatient endoscopy suite.

Motus GI Announces First Patient Enrolled in a Pilot Study Using the Pure-Vu® System for Patients with Lower GI Bleeding Being Conducted by a Leading U.S. Medical Center

FORT LAUDERDALE, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its fourth quarter and full year 2020 financial results on Tuesday, March 16, 2021, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.

Motus GI to Release Fourth Quarter and Full Year 2020 Results and Provide a Business Update on March 16

FORT LAUDERDALE, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate at the two upcoming virtual investor conferences in March 2021.

Motus GI to Participate in Two Upcoming Investor Conferences in March 2021

FORT LAUDERDALE, Fla., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has signed a warrant exercise agreement with an existing institutional investor that is expected to provide the Company with gross proceeds of up to $11.0 million.

Motus GI Announces Warrant Exercise Agreement Resulting in Expected Gross Proceeds to the Company of up to $11 Million

Regulatory approval for enhanced system is a key milestone that supports evaluation of strategic partnership opportunities in the EU - - - U.S. commercial rollout of Pure-Vu® GEN2 System enhancements initiated in Q4 2020

Motus GI Announces European Clearance of Enhanced Pure-Vu® GEN2 System to Harmonize with U.S. Configuration

Receives additional EU Patent for the Pure-Vu® System that protects the design of its fecal waste evacuation channels Receives additional EU Patent for the Pure-Vu® System that protects the design of its fecal waste evacuation channels

Motus GI Expands Intellectual Property Portfolio with U.S. Patent for the Pure-Vu® System's Universal Method to Mount on the End of Most Commercial Colonoscopes

FORT LAUDERDALE, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate in the Piper Sandler 32nd Annual Healthcare Conference, which is scheduled to take place virtually from December 1-3, 2020.

Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference

Motus GI Holdings, Inc.'s (MOTS) CEO Tim Moran on Q3 2020 Results - Earnings Call Transcript

FORT LAUDERDALE, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate update.

News for Motus GI Hlds Stock (MOTS)